CENTRE FOR COMMERCIALIZATION OF CANCER IMMUNOTHERAPY
Centre for Commercialization of Cancer Immunotherapy is to Accelerate the discovery, commercialization, and access to Cancer Immunotherapy.
CENTRE FOR COMMERCIALIZATION OF CANCER IMMUNOTHERAPY
Social Links:
Industry:
Biotechnology Health Care Life Science
Founded:
2015-01-01
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Euro Google Maps WordPress 6.0
Similar Organizations
Beta Pharma
Beta Pharma is an emerging pharmaceutical company dedicated to the discovery,and commercialization of innovative late stage therapies
Brain Neurotherapy Bio
Brain Neurotherapy Bio focuses on the clinical translation and development of neurotrophic factor gene therapy.
Centers for Age Control
Centers for Age Control develops Age Meter, an aging biomarker system that allows researchers to measure multiple biomarkers in a system.
Pivotal BioSciences
Pivotal BioSciences, Inc. is an emerging company dedicated to the development and commercialization of innovative cancer therapies.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-08-27 | Triumvira Immunologics | Centre for Commercialization of Cancer Immunotherapy investment in Series A - Triumvira Immunologics | 55 M USD |
More informations about "Centre for Commercialization of Cancer Immunotherapy"
New C3i Management Team Focuses on Next Phase of …
Jul 20, 2021 C3i Center Inc (Formerly known Centre for Commercialisation of Cancer Immunotherapy) is proud to announce three new additions to its executive team. Louisa Petropoulos has been appointed new Chief Executive Officer, …See details»
Government of Canada invests in bringing innovative cancer …
Jul 7, 2016 To support Canadians battling cancer, the Government of Canada is investing $15 million over five years in the Centre for Commercialization of Cancer Immunotherapy (C3i). …See details»
How C3i is Supporting Canada’s Home-Grown Innovation
Jun 3, 2021 Originally funded by the Canadian government in 2015 as a Centre of Excellence in Commercialization and Research (then called the Centre for Commercialization of Cancer Immunotherapy), C3i merges research expertise …See details»
Centre for Commercialization of Cancer Immunotherapy (C3i)
Immunotherapy is a rapidly emerging practice that harnesses the power of the immune system to combat cancer. It could revolutionize cancer care by developing nontoxic, highly efficient and …See details»
Key facts | Centre de recherche HMR - Gouvernement du Québec
10 research chairs. 2 centres that belong to the Networks of Centres of Excellence: Centre for Commercialization of Cancer Immunotherapy - C3i Regenerative Medicine and Cell Therapy …See details»
Centre for Commercialization of Cancer Immunotherapy and …
Jul 9, 2020 C3i is a funded Centre of Excellence in Commercialization and Research of the federal government’s Networks of Centres of Excellence program. It accelerates the …See details»
C3i Centre For Commercialization Of Cancer Immunotherapy
C3i is a recently designated Centre of Excellence for Commercialization and Research (CECR) by the Network of Centres of Excellence (NCE) of Canada. C3i aims to accelerate the access of …See details»
Cancer immunotherapy, regenerative medicine and C3i
Aug 6, 2018 In this editorial, Arnaud Deladeriere and Denis-Claude Roy, Centre for Commercialization of Cancer Immunotherapy (QC, Canada), introduce the center. Cancer immunotherapy is a form of regenerative medicine The …See details»
Matching ExCELLirate Canada funding from The …
Jul 5, 2022 Partner organizations and institutions with expertise in cell therapy production, preclinical testing, standards development and training, and health policy include BioCanRx, CellCAN, Centre for Commercialization of …See details»
ExCELLirate Canada
The Canadian Cancer Trials Group will lead the project along side organizations and institutions with expertise in cell therapy production, preclinical testing, standards development and training, and health policy include BioCanRx, …See details»
Centre for Commercialization of Cancer Immunotherapy
Centre for Commercialization of Cancer Immunotherapy is to Accelerate the discovery, commercialization, and access to Cancer Immunotherapy. ... View contacts for Centre for …See details»
Centre for Commercialization of Cancer Immunotherapy and …
Jul 29, 2020 It accelerates the development of cancer immunotherapies and cellular-based therapies by providing one-stop-shop services in the chain of product development through to …See details»
IRICoR and C3i Announce Partnership to Identify novel Tumor …
Apr 5, 2017 The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and the Centre for Commercialization of Cancer Immunotherapy (C3i) are …See details»
Triumvira Immunologics Announces Strategic Relationship for …
May 2, 2018 Established in 2016, the Centre for Commercialisation of Cancer Immunotherapy (C3i) is a Centre of Excellence for Commercialisation and Research from the Networks of …See details»
Quebec Drug Discovery Model Draws Global Attention
Created in 2008 as a not-for-profit Centre of Excellence for Commercialization and Research (CECR), IRICoR specializes in drug discovery. Its mandate is to accelerate the development …See details»
Commercialization of cellular immunotherapies for cancer
Apr 15, 2016 Successful commercialization of a cell therapy requires more than proving safety and efficacy to the regulators. The inherent complexity of cellular products delivers particular …See details»
Karen Knudsen, MBA PhD, Appointed Chief Executive Officer of …
SAN FRANCISCO, March 31, 2025 – The Parker Institute for Cancer Immunotherapy (PICI) today announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive …See details»
Cancer chemoprevention: signaling pathways and strategic …
Apr 18, 2025 Natural compounds have become a natural treasure reservoir for cancer chemoprevention because of their superior ease of availability, cost-effectiveness, and safety.See details»
Centre for Commercialization of Cancer Immunotherapy
Mar 15, 2023 Centre for Commercialization of Cancer Immunotherapy has made 2 investments. Their most recent investment was on Mar 15, 2023 , when Inspire Biotherapeutics raised a …See details»
Pembrolizumab With Chemoradiotherapy for Locally Advanced …
Mar 4, 2025 Cervical cancer is the fourth most common cancer in people assigned female sex at birth worldwide with an estimated incidence of 660 000 cases in 2022 and 13 820 cases in the …See details»